Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load
- PMID: 21858846
- DOI: 10.1002/hep.24615
Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load
Abstract
Loss of hepatitis B surface antigen (HBsAg) usually indicates the cure of hepatitis B virus (HBV) infection. In spontaneous hepatitis B e antigen (HBeAg) seroconverters, lower serum HBsAg and HBV DNA levels have been shown to be associated with HBsAg loss over time. However, little is known about their impacts on HBsAg loss in HBeAg-negative patients with limited viral replication. A total of 688 HBeAg-negative patients with baseline serum HBV DNA levels <2000 IU/mL were enrolled in Taiwan. The relationships of HBsAg and HBV DNA levels with subsequent HBsAg loss were investigated. In a mean follow-up of 11.6 years, the average annual rate of HBsAg loss was 1.6%. Baseline HBsAg and HBV DNA levels were inversely associated with subsequent HBsAg loss. When compared to patients who had HBsAg levels >1000 IU/mL, the rates of HBsAg loss were significantly higher in patients with HBsAg levels of 100-999, 10-99, and <10 IU/mL, with hazard ratios of 2.5 (95% confidence interval [CI], 1.6-4.0), 2.8 (95% CI, 1.6-5.0), and 13.2 (95% CI, 8.1-21.5), respectively. Multivariate analysis showed that HBsAg level, but not HBV DNA, remained as an independent factor. The adjusted hazard ratio of HBsAg loss was 13.2 (95% CI, 7.8-22.1) for HBsAg level <10 versus ≥ 1000 IU/mL. When compared to HBV DNA level by receiver operating characteristic curve analysis, HBsAg level served as a better predictor of both 5-year and 10-year HBsAg loss.
Conclusion: In HBeAg-negative patients with HBV genotype B or C infection who have HBV DNA level <2000 IU/mL, HBsAg level <10 IU/mL is the strongest predictor of HBsAg loss.
Copyright © 2011 American Association for the Study of Liver Diseases.
Similar articles
-
Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.Gastroenterology. 2011 Aug;141(2):517-25, 525.e1-2. doi: 10.1053/j.gastro.2011.04.046. Epub 2011 Apr 28. Gastroenterology. 2011. PMID: 21672542
-
Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.J Gastroenterol Hepatol. 2014 Jun;29(6):1242-9. doi: 10.1111/jgh.12502. J Gastroenterol Hepatol. 2014. PMID: 24384028
-
Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.Hepatology. 2013 Feb;57(2):441-50. doi: 10.1002/hep.26041. Epub 2012 Dec 6. Hepatology. 2013. PMID: 22941922
-
Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
-
What can we learn from hepatitis B virus clinical cohorts?Liver Int. 2015 Jan;35 Suppl 1:91-9. doi: 10.1111/liv.12716. Liver Int. 2015. PMID: 25529093 Review.
Cited by
-
New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection.Gastroenterology. 2019 Jan;156(2):355-368.e3. doi: 10.1053/j.gastro.2018.11.037. Epub 2018 Nov 22. Gastroenterology. 2019. PMID: 30472225 Free PMC article. Review.
-
HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection.World J Gastroenterol. 2014 Jun 28;20(24):7644-52. doi: 10.3748/wjg.v20.i24.7644. World J Gastroenterol. 2014. PMID: 24976702 Free PMC article. Review.
-
Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues.World J Gastroenterol. 2014 Jun 28;20(24):7686-95. doi: 10.3748/wjg.v20.i24.7686. World J Gastroenterol. 2014. PMID: 24976706 Free PMC article. Review.
-
Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach.Mol Biol Rep. 2021 Jan;48(1):843-854. doi: 10.1007/s11033-020-06056-4. Epub 2020 Dec 9. Mol Biol Rep. 2021. PMID: 33296069 Review.
-
Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.BMC Infect Dis. 2013 Oct 3;13:458. doi: 10.1186/1471-2334-13-458. BMC Infect Dis. 2013. PMID: 24090287 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources